Henrike Feuersenger Selected Research

Sepsis (Septicemia)

9/2018

Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: Safety findings from the COMPACT trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Henrike Feuersenger Research Topics

Disease

10	Hereditary Angioedemas 05/2024 - 05/2015
5	Angioedema 01/2022 - 09/2018
1	Injection Site Reaction 09/2018
1	Hypersensitivity (Allergy) 09/2018
1	Bacteremia 09/2018
1	Sepsis (Septicemia) 09/2018
1	Atrial Fibrillation 04/2011

Drug/Important Bio-Agent (IBA)

3	Factor XIIa (Coagulation Factor XIIa)IBA 05/2024 - 01/2022
3	Monoclonal AntibodiesIBA 05/2024 - 01/2022
2	Immunoglobulins (Immunoglobulin)IBA 05/2024 - 01/2022
2	AntibodiesIBA 09/2018 - 11/2016
2	Complement C1 Inhibitor Protein (C1 Esterase Inhibitor)IBA 01/2017 - 05/2015
1	A-factor (Streptomyces)IBA 01/2023
1	Factor XII (Hageman Factor)IBA 01/2022
1	BradykininIBA 01/2022
1	Brain Natriuretic Peptide (Natrecor)FDA Link 04/2011

Therapy/Procedure

5	Therapeutics 01/2023 - 09/2018
1	Polypharmacy 01/2020